Depression Clinical Trial
Official title:
An Investigation Examining the Evidence for Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder
This study will examine whether mitochondrial function is impaired in patients with bipolar
disorder. Mitrochondria are small organelles inside the cell that are responsible for energy
production. Recent studies in animals and humans suggest that abnormalities of mitrochondria
may be involved in bipolar depression. The study will also examine whether the food
supplement Coenzyme Q10 (CoQ10) improves mitochondrial function and symptoms such as
depressed mood, low energy, anxiety or slowness in thinking and movements in bipolar
patients. CoQ10 has been used to increase cell energy production and as an antioxidant. It
has had some benefit in patients with Parkinson's disease and migraine and in prolonging
survival in patients with cancer and heart failure.
Patients 18-65 years of age with bipolar disorder who are currently in a depressive episode
of at least 4 weeks duration may be eligible for this study. The study has four phases, as
follows:
Phase I: Medication Withdrawal
Patients taper off all psychotropic medications, usually over 1 to 2 weeks.
Phase II: Baseline Evaluation
After being off all medication for about 2 weeks, patients undergo the following procedures:
- Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). The two
procedures are performed in an MRI scanner. Both tests use a strong magnetic field and
radio waves to obtain images that provide information on brain anatomy and chemistry.
- Blood tests to assess mitochondrial function isolated from blood cells.
- Skin biopsy for tests of mitochondria. A small sample of skin tissue 5 x 5 millimeters
is surgically removed.
Phase III: Administration of CoQ10 or Placebo
Participants are randomly assigned to take either CoQ10 or placebo (an inactive look-alike
substance) twice a day by mouth. While taking the study medication, patients have the
following procedures periodically:
- Rating scales for anxiety and depression and adverse events.
- Check of vital signs.
- Blood and urine sample collections.
Phase IV: Study Completion
At the end of the 8 weeks of treatment, patients have a physical examination and
electrocardiogram, and the procedures in phase II are repeated. Participants may then
receive short-term treatment (up to 12 weeks) with medications for bipolar depression,
followed by referred to a community physician for long-term treatment.
Bipolar affective disorder is a common, severe, chronic and often life-threatening illness.
The depressive phase contributes to the majority of morbidity and mortality in this illness.
Impairments in physical and social functioning resulting from depression are often as severe
as other chronic medical illnesses. Few of the treatments in use have resulted from an
understanding of the pathophysiology of bipolar disorder. Undoubtedly, a greater
understanding of the pathophysiology of bipolar disorder will lead to improved treatments.
Current theories of depression suggest that mood disorders are associated with impairments
of cellular resilience and structural plasticity possibly a result of abnormal cellular
energy metabolism. Studies with Magnetic Resonance Spectroscopy (MRS) in bipolar subjects
show reduced brain intracellular pH and reduced ATP. Cellular energy generated by
mitochondrial oxidative phosphorylation from glucose via the electron transport chain is
stored as ATP, which provide neurons and glia with energy required to maintain their
function. Mitochondrial dysfunction and its inability to compensate for increase in ATP
demand might lead to impaired cellular resilience believed to be involved in the
pathophysiology of bipolar disorder. Abnormal regulation of nuclear genes coding for
mitochondrial proteins in the hippocampus of bipolar subjects provides further evidence of
mitochondrial dysfunction in bipolar disorder.
Coenzyme Q10 (CoQ10) is an essential cofactor in the mitochondrial electron transport chain
necessary for cellular energy generation. Exogenous administration of CoQ10 attenuates ATP
depletion and has anti-oxidant properties. In light of the above evidence, we hypothesize
that bipolar disorder is associated with mitochondrial dysfunction as evidenced by impaired
brain energy metabolism and that administration of CoQ10, a mitochondrial enhancer, will
restore mitochondrial function. To accomplish these objectives, we will compare
mitochondrial functions in bipolar depressed subjects to 26 healthy controls matched for
age, gender and BMI. Measures of mitochondrial function will include brain lactate levels (a
product of anaerobic glycolysis) with H+ MRS, 2) assays of mitochondrial function in
cultured fibroblasts and platelets, and 3) gene expression of mitochondrial and nuclear
genes using a cDNA Microarray. Further, subjects with bipolar depression, ages 18 to 65 will
be randomized to either CoQ10 (300-1200 mg/day) or placebo in a double-blind placebo
controlled trial for a period of 8 weeks. Measures of mitochondrial function will be
compared between subjects randomized to placebo or CoQ10 at baseline and at the end of the
8-week trial.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |